OMERS ADMINISTRATION Corp purchased a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 13,953 shares of the medical instruments supplier’s stock, valued at approximately $5,009,000.
A number of other institutional investors and hedge funds have also made changes to their positions in WST. Addison Advisors LLC purchased a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at about $28,000. Avalon Trust Co purchased a new position in West Pharmaceutical Services in the second quarter worth about $28,000. Elyxium Wealth LLC purchased a new position in West Pharmaceutical Services in the fourth quarter worth about $25,000. Bayban bought a new stake in West Pharmaceutical Services during the fourth quarter worth approximately $27,000. Finally, DV Equities LLC bought a new stake in West Pharmaceutical Services during the fourth quarter worth approximately $28,000. 93.90% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on WST shares. Evercore reaffirmed an “outperform” rating and issued a $425.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Wolfe Research started coverage on West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 target price on the stock. TD Cowen restated a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Zacks Research downgraded West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, KeyCorp lifted their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $368.08.
West Pharmaceutical Services Stock Up 0.1%
Shares of NYSE:WST opened at $353.33 on Tuesday. The firm has a market capitalization of $24.87 billion, a PE ratio of 45.24, a price-to-earnings-growth ratio of 2.47 and a beta of 1.15. The business has a 50 day simple moving average of $349.06 and a two-hundred day simple moving average of $301.06. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. During the same period in the prior year, the business posted $1.84 earnings per share. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities analysts predict that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.
West Pharmaceutical Services Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were paid a $0.22 dividend. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.27%.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Recommended Stories
- Five stocks we like better than West Pharmaceutical Services
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
